{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:32:47Z","timestamp":1791019967835,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10787-020-00697-4","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T14:02:55Z","timestamp":1583848975000},"page":"711-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et\u2019s syndrome"],"prefix":"10.1007","volume":"28","author":[{"given":"Elena","family":"Silvestri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bitossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bettiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Di Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bacherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Vannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"697_CR1","doi-asserted-by":"publisher","first-page":"1623847","DOI":"10.1155\/2019\/1623847","volume":"2019","author":"A Bitossi","year":"2019","unstructured":"Bitossi A, Bettiol A, Silvestri E et al (2019) Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediators Inflamm 2019:1623847. https:\/\/doi.org\/10.1155\/2019\/1623847","journal-title":"Mediators Inflamm"},{"key":"697_CR2","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447\u20132451. https:\/\/doi.org\/10.1002\/art.21197","journal-title":"Arthritis Rheum"},{"key":"697_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1126\/science.1071924","volume":"296","author":"G Chen","year":"2002","unstructured":"Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634\u20131635. https:\/\/doi.org\/10.1126\/science.1071924","journal-title":"Science"},{"key":"697_CR4","first-page":"9","volume":"38","author":"ET Cunningham","year":"1997","unstructured":"Cunningham ET, Stalder A, Sanna PP et al (1997) Localization of tumor necrosis factor receptor messenger RNA in normal and herpes simplex virus-infected mouse eyes. Invest Ophthalmol Vis Sci 38:9\u201315","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"697_CR5","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-de-Vicu\u00f1a C et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575\u20131581. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.018","journal-title":"Ophthalmology"},{"key":"697_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","volume":"97","author":"BC Dobner","year":"2013","unstructured":"Dobner BC, Max R, Becker MD et al (2013) A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 97:134\u2013138. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301401","journal-title":"Br J Ophthalmol"},{"key":"697_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","volume":"25","author":"K Durrani","year":"2017","unstructured":"Durrani K, Kempen JH, Ying G-S et al (2017) Adalimumab for ocular inflammation. Ocul Immunol Inflamm 25:405\u2013412. https:\/\/doi.org\/10.3109\/09273948.2015.1134581","journal-title":"Ocul Immunol Inflamm"},{"key":"697_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11739-019-02154-9","volume":"14","author":"G Emmi","year":"2019","unstructured":"Emmi G, Prisco D (2019) Beh\u00e7et\u2019s syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments. Intern Emerg Med 14:639\u2013643. https:\/\/doi.org\/10.1007\/s11739-019-02154-9","journal-title":"Intern Emerg Med"},{"key":"697_CR9","unstructured":"European Medicine Agency. Adalimumab\u2014summary of product characteristics"},{"key":"697_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183\u2013189. https:\/\/doi.org\/10.1007\/s10067-016-3480-x","journal-title":"Clin Rheumatol"},{"key":"697_CR11","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s10067-016-3426-3","volume":"35","author":"C Fabiani","year":"2016","unstructured":"Fabiani C, Vitale A, Lopalco G et al (2016) Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 35:2631\u20132638. https:\/\/doi.org\/10.1007\/s10067-016-3426-3","journal-title":"Clin Rheumatol"},{"key":"697_CR12","first-page":"301","volume":"37","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Rigante D et al (2019) Efficacy of anti-tumour necrosis factor-\u03b1 monoclonal antibodies in patients with non-infectious anterior uveitis. Clin Exp Rheumatol 37:301\u2013305","journal-title":"Clin Exp Rheumatol"},{"key":"697_CR13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","volume":"37","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Vitale A, Rigante D et al (2018) Predictors of sustained clinical response in patients with Beh\u00e7et\u2019s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol 37:1715\u20131720. https:\/\/doi.org\/10.1007\/s10067-018-4092-4","journal-title":"Clin Rheumatol"},{"key":"697_CR14","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jfo.2017.11.003","volume":"41","author":"J Gueudry","year":"2018","unstructured":"Gueudry J, Muraine M (2018) Anterior uveitis J Fr Ophtalmol 41:e11\u2013e21","journal-title":"Anterior uveitis J Fr Ophtalmol"},{"key":"697_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/2008-322X.156110","volume":"10","author":"ML Hern\u00e1ndez Garfella","year":"2015","unstructured":"Hern\u00e1ndez Garfella ML, Palomares Fort P, Rom\u00e1n Ivorra JA, Cervera Taulet E (2015) Aqueous humor levels of different interleukins 1-\u03b2, 2, 6 and 10, tumor necrosis factor-\u03b1 and vascular endothelial growth factor in uveitis treated with adalimumab. J Ophthalmic Vis Res 10:49\u201354. https:\/\/doi.org\/10.4103\/2008-322X.156110","journal-title":"J Ophthalmic Vis Res"},{"key":"697_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375:932\u2013943. https:\/\/doi.org\/10.1056\/NEJMoa1509852","journal-title":"N Engl J Med"},{"issue":"12","key":"697_CR17","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1136\/bjophthalmol-2017-311234","volume":"102","author":"JT Lee","year":"2018","unstructured":"Lee JT, Yates WB, Rogers S et al (2018) Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol 102(12):1672\u20131678. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311234","journal-title":"Br J Ophthalmol"},{"key":"697_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet (Lond, Engl) 388:1183\u20131192. https:\/\/doi.org\/10.1016\/S0140-6736(16)31339-3","journal-title":"Lancet (Lond, Engl)"},{"key":"697_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","volume":"135","author":"J Sheppard","year":"2017","unstructured":"Sheppard J, Joshi A, Betts KA et al (2017) Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol 135:511\u2013518. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0603","journal-title":"JAMA Ophthalmol"},{"key":"697_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/exer.1996.0120","volume":"63","author":"BD Sippy","year":"1996","unstructured":"Sippy BD, Hofman FM, Wright AD et al (1996) Soluble tumor necrosis factor receptors are present in human vitreous and shed by retinal pigment epithelial cells. Exp Eye Res 63:311\u2013317. https:\/\/doi.org\/10.1006\/exer.1996.0120","journal-title":"Exp Eye Res"},{"key":"697_CR21","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP et al (2018) Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology 125:1075\u20131087. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.039","journal-title":"Ophthalmology"},{"key":"697_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","volume":"97","author":"EB Suhler","year":"2013","unstructured":"Suhler EB, Lowder CY, Goldstein DA et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97:481\u2013486. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302292","journal-title":"Br J Ophthalmol"},{"key":"697_CR23","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.ophtha.2017.06.017","volume":"124","author":"EB Suhler","year":"2017","unstructured":"Suhler EB, Thorne JE, Mittal M et al (2017) Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis. Ophthalmology 124:1799\u20131807. https:\/\/doi.org\/10.1016\/j.ophtha.2017.06.017","journal-title":"Ophthalmology"},{"key":"697_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun 62:67\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005","journal-title":"J Autoimmun"},{"issue":"7","key":"697_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/13543784.2016.1181751","volume":"25","author":"A Vitale","year":"2016","unstructured":"Vitale A, Rigante D, Lopalco G et al (2016) New therapeutic solutions for Beh\u00e7et\u2019s syndrome. Expert Opin Investig Drugs 25(7):827\u2013840","journal-title":"Expert Opin Investig Drugs"},{"key":"697_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s0898-6568(01)00160-7","volume":"13","author":"H Wajant","year":"2001","unstructured":"Wajant H, Henkler F, Scheurich P (2001) The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 13:389\u2013400. https:\/\/doi.org\/10.1016\/s0898-6568(01)00160-7","journal-title":"Cell Signal"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-020-00697-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T01:03:54Z","timestamp":1615338234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-020-00697-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1007\/s10787-020-00697-4","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standardsEthics approval"}},{"value":"The authors declare that they have no conflict of interest.Ethical approval was waived by the ethics committee of Careggi University Hospital (CEAVC Reference number: 13366). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. In view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}